CytoSorbents Corp (CTSO):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:CytoSorbents Corp (CTSO) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C6618
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that develops blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriously ill patients by reducing excessive cytokines and bacterial toxins. CytoSorbents’ CytoSorb is also being administered during and after cardiac surgery to prevent post-operative complications such as multiple organ failure. The company offers VetResQ, a blood purification adsorber, to support and treat excessive inflammation and toxic injury in animals. The company offers its products through a network of distributors across Europe, the Middle East and Asia Pacific. CytoSorbents is headquartered in Monmouth Junction, New Jersey, the US.

CytoSorbents Corp (CTSO) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CytoSorbents Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
CytoSorbents Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 7
CytoSorbents Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
CytoSorbents Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
CytoSorbents Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
CytoSorbents Corp, Medical Equipment, Deal Details 11
Partnerships 11
CytoSorbents Enters into Agreement with Dr. Reddy’s Labs 11
CytoSorbents Enters into Distribution Agreement with Armaghan Salamat Kish 12
Terumo Cardiovascular Enters into Agreement with CytoSorbents 13
CytoSorbents Partners with NHLBI for HemoDefend 14
CytoSorbents Enters Into Research Agreement With University of Pennsylvania School Of Veterinary Medicine 15
Equity Offering 16
Cytosorbents Plans to Raise up to USD150 Million in Public Offering of Securities 16
CytoSorbents Raises USD10 Million in Public Offering of Shares 17
CytoSorbents Raises USD10 Million in Public Offering of Shares 19
CytoSorbents Completes Private Placement Of Units For US$10.2 Million 20
CytoSorbents Completes Private Placement Of Common Stock For US$4 Million 21
Debt Offering 22
CytoSorbents Completes Private Placement Of Notes Due 2014 For US$1.1 Million 22
Cytosorbents Raises USD0.7 Million in Private Placement of 8% Notes 23
CytoSorbents Corp – Key Competitors 24
CytoSorbents Corp – Key Employees 25
CytoSorbents Corp – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 02, 2018: CytoSorbents achieves record total revenue and CytoSorb sales in the second quarter 2018 27
May 08, 2018: CytoSorbents Reports Strong First Quarter 2018 Financial Results 32
Mar 08, 2018: CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017 33
Jan 08, 2018: CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter 36
Nov 09, 2017: CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017 38
Aug 07, 2017: CytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017 43
May 08, 2017: CytoSorbents Reports First Quarter 2017 Financial Results 47
Mar 03, 2017: CytoSorbents Reports Record Quarterly and Full-Year 2016 Revenue 48
Jan 10, 2017: CytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results 49
Corporate Communications 50
Dec 19, 2017: CytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 50
Jul 05, 2017: CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank 51
May 30, 2017: Dr. Eric G. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer 52
Mar 22, 2017: Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins Cytosorbents Scientific Advisory Board 53
Product News 54
Sep 05, 2017: Cytosorbents Highlights Important Research Advances in Traumatic Brain Injury, Hemorrhagic Shock, and Severe Hyperkalemia at the Military Health System Research Symposium 54
Mar 08, 2017: Cytosorbents Highlights Activities At The 22nd International Conference On Advances In Critical Care Nephrology 56
Other Significant Developments 57
Feb 05, 2018: MedaPhor Group: Innovate UK grant award confirmed 57
Jul 13, 2017: CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
CytoSorbents Corp, Medical Equipment, Key Facts, 2017 2
CytoSorbents Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
CytoSorbents Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
CytoSorbents Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 7
CytoSorbents Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
CytoSorbents Corp, Deals By Market, 2012 to YTD 2018 9
CytoSorbents Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
CytoSorbents Enters into Agreement with Dr. Reddy's Labs 11
CytoSorbents Enters into Distribution Agreement with Armaghan Salamat Kish 12
Terumo Cardiovascular Enters into Agreement with CytoSorbents 13
CytoSorbents Partners with NHLBI for HemoDefend 14
CytoSorbents Enters Into Research Agreement With University of Pennsylvania School Of Veterinary Medicine 15
Cytosorbents Plans to Raise up to USD150 Million in Public Offering of Securities 16
CytoSorbents Raises USD10 Million in Public Offering of Shares 17
CytoSorbents Raises USD10 Million in Public Offering of Shares 19
CytoSorbents Completes Private Placement Of Units For US$10.2 Million 20
CytoSorbents Completes Private Placement Of Common Stock For US$4 Million 21
CytoSorbents Completes Private Placement Of Notes Due 2014 For US$1.1 Million 22
Cytosorbents Raises USD0.7 Million in Private Placement of 8% Notes 23
CytoSorbents Corp, Key Competitors 24
CytoSorbents Corp, Key Employees 25
CytoSorbents Corp, Subsidiaries 26

List of Figures
CytoSorbents Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
CytoSorbents Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
CytoSorbents Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
CytoSorbents Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
CytoSorbents Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
CytoSorbents Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
CytoSorbents Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
CytoSorbents Corp, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[CytoSorbents Corp (CTSO):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pivotal Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pivotal Therapeutics Inc (Pivotal Therapeutics) is a pharmaceutical company that develops and markets Omega-3 based therapies and therapeutic products for cardiovascular disorders. The company offers products such as VASCAZEN, a medical food formulated for the dietary management of an Omega- …
  • Audentes Therapeutics Inc (BOLD)-製薬・医療分野:企業M&A・提携分析
    Summary Audentes Therapeutics Inc (Audentes) is a biotechnology company that focuses on the development and commercialization of gene therapy products for serious and life-threatening rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myop …
  • Medeon Biodesign Inc (6499):医療機器:M&Aディール及び事業提携情報
    Summary Medeon Biodesign Inc (Medeon Biodesign) is a medical device company that develops patient-centered medical device products that address unmet medical needs. The company’s products include cardiovascular devices and equipment, devices for minimally invasive surgeries, laparoscopic device, hig …
  • Central Japan Railway Company:企業の戦略・SWOT・財務情報
    Central Japan Railway Company - Strategy, SWOT and Corporate Finance Report Summary Central Japan Railway Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Chembio Diagnostic, Inc. (CEMI)-医療機器分野:企業M&A・提携分析
    Summary Chembio Diagnostic, Inc. (Chembio) develops, manufactures, markets and licenses point-of-care diagnostic (POCs) tests for the detection of infectious diseases. The company offers products to prevent the spread of infectious diseases with solutions like Dual Path Platform (DPP), which makes P …
  • Manchester United Plc:企業の戦略・SWOT・財務情報
    Manchester United Plc - Strategy, SWOT and Corporate Finance Report Summary Manchester United Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Verisante Technology Inc:企業の製品パイプライン分析2018
    Summary Verisante Technology Inc (Verisante) is a medical device company that develops and commercializes systems for the early detection of cancer. The company’s key product offerings include Verisante Aura, Verisante Core and Verisante MSI Camera. The Verisante Aura is used for skin cancer detecti …
  • Clarins SA:企業の戦略・SWOT・財務情報
    Clarins SA - Strategy, SWOT and Corporate Finance Report Summary Clarins SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • FleetCor Technologies Inc:企業の戦略・SWOT・財務分析
    FleetCor Technologies Inc - Strategy, SWOT and Corporate Finance Report Summary FleetCor Technologies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • CA, Inc.:企業のM&A・事業提携・投資動向
    CA, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CA, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • AF AB (AF B):電力:M&Aディール及び事業提携情報
    Summary AF AB is an engineering and consulting company. It offers various services such as product development and IT support to several sectors including automotive, telecom, defense and life sciences. The company also provides services such as communications systems management, development of cust …
  • Arkansas Children’s Hospital:企業の戦略的SWOT分析
    Arkansas Children's Hospital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Maverick Natural Resources LLC:企業の戦略的SWOT分析
    Maverick Natural Resources LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Active Motif Inc:医療機器:M&Aディール及び事業提携情報
    Summary Active Motif Inc (Active Motif) is a healthcare company that develops and delivers biological research tools. The company’s products include extracts, antibodies, reporter assays, fluorescent dyes, kits, cell, acid, and tissue extracts, molecules and recombinant proteins, among others. It of …
  • Barclays:企業の戦略・SWOT・財務情報
    Barclays - Strategy, SWOT and Corporate Finance Report Summary Barclays - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Screen Holdings Co Ltd (7735):企業の財務・戦略的SWOT分析
    Screen Holdings Co Ltd (7735) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Theranexus SAS (ALTHX):製薬・医療:M&Aディール及び事業提携情報
    Summary Theranexus SAS (Theranexus) is a biotechnology company that discovers and develops drug combinations for safe and efficient neurological and psychiatric treatments. The company develops THN102, a pipeline product that comprises modafinil. It also offers THN02 for the treatment of sleepiness …
  • RBC Bearings Inc (ROLL):企業の財務・戦略的SWOT分析
    Summary RBC Bearings Inc (RBC Bearings) is an equipment manufacturing company that deals with the production and distribution of engineered precision bearings and products. The company's industrial product portfolio include ball bearings, cam followers, collets and toolholders, pins, rollers, shafts …
  • Fidelity Life Assurance of Zimbabwe Ltd:企業の戦略・SWOT・財務情報
    Fidelity Life Assurance of Zimbabwe Ltd - Strategy, SWOT and Corporate Finance Report Summary Fidelity Life Assurance of Zimbabwe Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Syndax Pharmaceuticals Inc (SNDX):企業の財務・戦略的SWOT分析
    Summary Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate includes entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for the tre …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆